The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of the ADAPT strategy on dormant CD133+ colon cancer stem cells (CSC) and molecular complete remission measured by peripheral blood mononuclear (PBMC) CD133 mRNA.
Edward H. Lin
Consultant or Advisory Role - Apomax Biolab
Stock Ownership - Apomax Biolab
Yu Xiazhen
No relevant relationships to disclose
Xi C He
No relevant relationships to disclose
Xifeng Wu
Consultant or Advisory Role - Apomax Biolab (U)
Yang Xie
No relevant relationships to disclose
Yanhong Deng
No relevant relationships to disclose
Guang Yang
No relevant relationships to disclose
Qiang Tian
Consultant or Advisory Role - Apomax Biolab
Lingheng Li
No relevant relationships to disclose